Form 4: Twist Bioscience CEO Emily Leproust Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Twist Bioscience CEO Emily Leproust sold 7,968 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Emily M. Leproust, CEO of Twist Bioscience, sold 7,968 shares of common stock at a price of $47.998 per share on November 11, 2024.
- The sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
- This transaction was not a discretionary trade but rather a mandated sale by the company's equity incentive plan.
- Following the transaction, Leproust directly owns 581,584 shares of Twist Bioscience common stock.
- Leproust also holds various employee stock options with different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine filing related to insider transactions and is common for executives who receive equity compensation. It does not indicate any change in the company's performance or outlook.
Comparison to Industry Standards
- The sale of shares to cover tax obligations is a standard practice among executives at publicly traded companies.
- Many companies use 'sell to cover' mechanisms as part of their equity compensation plans.
- The vesting schedules and option prices are typical for employee stock options in the biotech industry.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to one of the employee stock options vested. |
| 09/28/2017 | 10% of shares subject to one of the employee stock options vested. |
| 09/28/2018 | 15% of shares subject to one of the employee stock options vested. |
| 10/31/2019 | 20% of shares subject to one of the employee stock options vested. |
| 10/24/2020 | 25% of shares subject to one of the employee stock options vested. |
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 11/11/2024 | Date of the reported stock sale by Emily Leproust. |
| 11/13/2024 | Date the Form 4 was signed. |
Keywords
Twist Bioscience, Emily Leproust, stock sale, Form 4, insider trading, equity compensation, tax withholding, restricted stock units, employee stock options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.